We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
Cap. Flow
-$2.03B
Cap. Flow %
-2.75%
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$60.7M
2
ADI icon
Analog Devices
ADI
+$46.1M
3
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$37.3M
4
MTCH icon
Match Group
MTCH
+$28.2M
5
GXO icon
GXO Logistics
GXO
+$19.7M

Sector Composition

Rank Sector Weight
1 Technology 23.91%
2 Financials 14.2%
3 Healthcare 13.07%
4 Consumer Discretionary 12.09%
5 Communication Services 9.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MTEM
2876
DELISTED
Molecular Templates, Inc.
MTEM
$218K ﹤0.01%
2,167
+89
+4% +$9.18K
UAVS icon
2877
AgEagle Aerial Systems
UAVS
$53.9M
$217K ﹤0.01%
72
+3
+4% +$11.1K
OBDC icon
2878
Blue Owl Capital
OBDC
$5.74B
$216K ﹤0.01%
+15,314
New +$222K
CASA
2879
DELISTED
Casa Systems, Inc. Common Stock
CASA
$216K ﹤0.01%
31,883
+999
+3% +$7.37K
DNUT icon
2880
Krispy Kreme
DNUT
$577M
$215K ﹤0.01%
+15,326
New +$246K
SONY icon
2881
Sony
SONY
$138B
$215K ﹤0.01%
+9,705
New +$203K
STXS icon
2882
Stereotaxis
STXS
$141M
$215K ﹤0.01%
39,906
+1,796
+5% +$13.5K
TMCI icon
2883
Treace Medical Concepts
TMCI
$309M
$215K ﹤0.01%
8,005
+525
+7% +$14.4K
AXDX
2884
DELISTED
Accelerate Diagnostics
AXDX
$214K ﹤0.01%
3,664
+115
+3% +$7.5K
KNTK icon
2885
Kinetik
KNTK
$7.98B
$214K ﹤0.01%
6,190
+192
+3% +$6.31K
PSTL
2886
Postal Realty Trust
PSTL
$699M
$213K ﹤0.01%
11,422
+434
+4% +$8.32K
TM icon
2887
Toyota
TM
$225B
$213K ﹤0.01%
+1,198
New +$214K
URG
2888
Ur-Energy
URG
$556M
$213K ﹤0.01%
124,050
+25,448
+26% +$34.1K
EBET
2889
DELISTED
EBET, INC. Common Stock
EBET
$213K ﹤0.01%
+212
New +$171K
LUNA
2890
DELISTED
Luna Innovations Incorporated
LUNA
$213K ﹤0.01%
22,454
+1,364
+6% +$14.7K
ONCR
2891
DELISTED
Oncorus, Inc.
ONCR
$212K ﹤0.01%
22,742
+950
+4% +$10.8K
FTSI
2892
DELISTED
FTS International, Inc. Common Stock
FTSI
$212K ﹤0.01%
8,603
+425
+5% +$9.7K
ALGS icon
2893
Aligos Therapeutics
ALGS
$34.9M
$211K ﹤0.01%
544
+42
+8% +$16.6K
FLXS icon
2894
Flexsteel Industries
FLXS
$311M
$211K ﹤0.01%
6,834
+425
+7% +$15.1K
TNYA icon
2895
Tenaya Therapeutics
TNYA
$163M
$211K ﹤0.01%
+10,222
New +$220K
FXLV
2896
DELISTED
F45 Training Holdings Inc.
FXLV
$211K ﹤0.01%
+14,136
New +$207K
DRIO icon
2897
DarioHealth
DRIO
$71.2M
$209K ﹤0.01%
766
+32
+4% +$9.23K
EWCZ
2898
DELISTED
European Wax Center
EWCZ
$209K ﹤0.01%
+7,474
New +$187K
FRBK
2899
DELISTED
Republic First Bancorp Inc
FRBK
$209K ﹤0.01%
67,748
+1,146
+2% +$3.98K
PZN
2900
DELISTED
Pzena Investment Management, Inc. Class A
PZN
$209K ﹤0.01%
21,202
+10
+0% +$107

Similar funds

RhumbLine Advisers's Q3 2021 Portfolio in Review

As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
  • RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
  • RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
  • RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
  • RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
  • RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
  • RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.

Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.